Logo image of APRE

APREA THERAPEUTICS INC (APRE) Stock Fundamental Analysis

NASDAQ:APRE - Nasdaq - US03836J2015 - Common Stock - Currency: USD

2.62  -0.22 (-7.75%)

Fundamental Rating

3

APRE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of APRE is average, but there are quite some concerns on its profitability. APRE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APRE has reported negative net income.
APRE had a negative operating cash flow in the past year.
APRE had negative earnings in each of the past 5 years.
APRE had a negative operating cash flow in each of the past 5 years.
APRE Yearly Net Income VS EBIT VS OCF VS FCFAPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of APRE (-50.22%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -58.08%, APRE is in the better half of the industry, outperforming 61.10% of the companies in the same industry.
Industry RankSector Rank
ROA -50.22%
ROE -58.08%
ROIC N/A
ROA(3y)-167.16%
ROA(5y)-116.02%
ROE(3y)-190.16%
ROE(5y)-132.44%
ROIC(3y)N/A
ROIC(5y)N/A
APRE Yearly ROA, ROE, ROICAPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APRE Yearly Profit, Operating, Gross MarginsAPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K -2.5K

More info and screens

6

2. Health

2.1 Basic Checks

APRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APRE has been increased compared to 1 year ago.
Compared to 5 years ago, APRE has more shares outstanding
APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APRE Yearly Shares OutstandingAPRE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
APRE Yearly Total Debt VS Total AssetsAPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -15.51, we must say that APRE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -15.51, APRE is not doing good in the industry: 82.95% of the companies in the same industry are doing better.
There is no outstanding debt for APRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.51
ROIC/WACCN/A
WACC9.44%
APRE Yearly LT Debt VS Equity VS FCFAPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

APRE has a Current Ratio of 7.28. This indicates that APRE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.28, APRE is doing good in the industry, outperforming 68.56% of the companies in the same industry.
A Quick Ratio of 7.28 indicates that APRE has no problem at all paying its short term obligations.
The Quick ratio of APRE (7.28) is better than 68.74% of its industry peers.
Industry RankSector Rank
Current Ratio 7.28
Quick Ratio 7.28
APRE Yearly Current Assets VS Current LiabilitesAPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.57% over the past year.
Looking at the last year, APRE shows a very strong growth in Revenue. The Revenue has grown by 129.97%.
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.58%
Revenue 1Y (TTM)129.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.17%

3.2 Future

Based on estimates for the next years, APRE will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.33% on average per year.
Based on estimates for the next years, APRE will show a very strong growth in Revenue. The Revenue will grow by 73.50% on average per year.
EPS Next Y34.9%
EPS Next 2Y27.25%
EPS Next 3Y15.89%
EPS Next 5Y13.33%
Revenue Next Year94.18%
Revenue Next 2Y14.24%
Revenue Next 3Y9.28%
Revenue Next 5Y73.5%

3.3 Evolution

APRE Yearly Revenue VS EstimatesAPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
APRE Yearly EPS VS EstimatesAPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APRE. In the last year negative earnings were reported.
Also next year APRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APRE Price Earnings VS Forward Price EarningsAPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APRE Per share dataAPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

APRE's earnings are expected to grow with 15.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.25%
EPS Next 3Y15.89%

More info and screens

0

5. Dividend

5.1 Amount

APRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APREA THERAPEUTICS INC

NASDAQ:APRE (2/21/2025, 8:01:29 PM)

2.62

-0.22 (-7.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-24 2025-03-24/amc
Inst Owners35%
Inst Owner Change-99.07%
Ins Owners11.85%
Ins Owner Change1.07%
Market Cap14.23M
Analysts84.44
Price Target15.98 (509.92%)
Short Float %1.02%
Short Ratio1.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.12%
Min EPS beat(2)10.45%
Max EPS beat(2)15.78%
EPS beat(4)3
Avg EPS beat(4)6.25%
Min EPS beat(4)-16.63%
Max EPS beat(4)15.78%
EPS beat(8)7
Avg EPS beat(8)22.01%
EPS beat(12)10
Avg EPS beat(12)8.67%
EPS beat(16)12
Avg EPS beat(16)6.43%
Revenue beat(2)2
Avg Revenue beat(2)528.24%
Min Revenue beat(2)54.52%
Max Revenue beat(2)1001.96%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)6.89%
Revenue NQ rev (1m)11.11%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.85
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0.24
BVpS4.28
TBVpS4.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.22%
ROE -58.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-167.16%
ROA(5y)-116.02%
ROE(3y)-190.16%
ROE(5y)-132.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.57%
Cap/Sales 1.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.28
Quick Ratio 7.28
Altman-Z -15.51
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.58%
EPS Next Y34.9%
EPS Next 2Y27.25%
EPS Next 3Y15.89%
EPS Next 5Y13.33%
Revenue 1Y (TTM)129.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.17%
Revenue Next Year94.18%
Revenue Next 2Y14.24%
Revenue Next 3Y9.28%
Revenue Next 5Y73.5%
EBIT growth 1Y-2.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.97%
EBIT Next 3Y-7.42%
EBIT Next 5Y-8.66%
FCF growth 1Y55.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.78%
OCF growth 3YN/A
OCF growth 5YN/A